2016 American Transplant Congress
Superior Waitlist and Equivalent Transplant Outcomes Among Hepatitis C RNA-Positive Patients Who Are Willing to Accept Hepatitis C Seropositive Kidneys.
Background: kidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is not clear how the acceptance/listing status…2016 American Transplant Congress
Evaluation of Long Term Outcome After Living Donor Liver Transplantation in Sequential 653 Recipients with or without Viral Infection: Is HBV & HCV Co-Infection Better Than the Monoinfection? A Single Center Retrospective Analysis.
Organ Transplantation, China Medical University Hospital, Taichung, Taiwan.
Background:End-stage liver disease secondary to HBV and HCV coinfection is not uncommon in Asia.However,long term outcome of such patients after living donor liver transplantation (LDLT)…2016 American Transplant Congress
Efficacy and Safety of Direct Antiviral Agents (DAA)-Based Therapies for Hepatitis C Virus (HCV) Infection in Kidney Transplant (KT) Recipients.
Background: The use of interferon-based regimens for HCV infection in KT recipients is limited due to the increased risk of acute graft rejection (AR), poor…2016 American Transplant Congress
DAAs Rapidly Clear HCV Viremia in Recipients of HCV+ Donor Kidneys.
Purpose: Direct acting antivirals (DAAs) have revolutionized the treatment of hepatitis C (HCV) in both general and liver transplant populations. However, data in kidney transplant…2016 American Transplant Congress
Clinical, Histologic and Charge Endpoints When Populations with Hepatitis C Recurrence Are Treated with Direct-Acting Antiviral or Interferon Based Therapies.
University of Kansas, Kansas City, KS.
Background: While the primary endpoint for patients transplanted for Hepatitis C (HCV) has been established as sustained virologic response (SVR), different pathways have existed to…2016 American Transplant Congress
Utilization of HCV-Positive Donors' Kidneys: Potential Benefits in the Era of Direct Acting Antiviral (DAA) Therapy.
Organ shortage and expanding kidney waiting list fostered utilization of HCV positive donors' organs (HCVD+). HCVD+ kidneys have slightly worse long term outcomes compared with…2016 American Transplant Congress
Utilization and Discard of HCV+ Donor Livers in the Advent of Direct-Acting Antiviral Therapy.
While 45% of liver candidates are hepatitis C (HCV)-antibody positive (+) and might benefit from a HCV+ donor liver, only a small proportion receive one.…2016 American Transplant Congress
Direct-Acting Antivirals for Hepatitis C Treatment in Kidney Transplant Recipients.
University of Minnesota, Minneapolis.
Background: Hepatitis C infection is associated with worse clinical outcomes in kidney transplant recipients. Direct-acting antivirals (DAAs) have been effectively used in liver transplant patients…2016 American Transplant Congress
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients with Chronic Genotype 1 or 4 HCV Infection.
Background and Aims: Interferon (IFN) and ribavirin (RBV) for the treatment of chronic hepatitis C (HCV) in kidney transplant recipients is complicated by the risk…2016 American Transplant Congress
High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.
Introduction: HCV infected patients with decompensated liver disease have significant morbidity & mortality. The efficacy & safety of LDV/SOF + RBV was evaluated in a…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 28
- Next Page »